Lise Jamieson

Lise Jamieson

scientist South Africa

Lise Jamieson is a leading researcher in the field of HIV prevention and epidemiology. She is known for her work on modeling the impact of new HIV prevention strategies, including the use of long-acting injectables, to reduce new infections, particularly among high-risk populations. Her research aims to inform public health policies and programmatic decisions to effectively combat the HIV epidemic.

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
0
Power
0$
Sentiment
0.00
Countries Mentioned

No country-level mention data available.

Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

South Africa South Africa: Lise Jamieson headed the study presented at the meeting discussing the allocation of lenacapavir shots. 7

Aaron Motsoaledi Dvora Joseph Davey Nonhlanhla Fikile Ndlovu
Mail & Guardian: SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them – The Mail & Guardian

South Africa South Africa: Lise Jamieson is a modelling scientist at the Health Economics and Epidemiology Research Office at Wits University. 7

Nonhlanhla Fikile Ndlovu Aaron Motsoaledi Glaudina Loots Thembisile Xulu Wendy Cupido Caroline Almeida
Mail & Guardian: SA wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch – The Mail & Guardian

South Africa South Africa: Lise Jamieson is HE2RO’s lead modeller discussing the distribution of the anti-HIV jab. 6

Anna Maria Van Niekerk Boitumelo Semete Makokotlela Gugu Shabangu Aaron Motsoaledi Dvora Joseph Davey Yogan Pillay
Mail & Guardian: The six-monthly anti-HIV jab could be in 360 clinics by February. Who should get the first doses? – The Mail & Guardian

South Africa South Africa: Lise Jamieson is the lead study author discussing the need for high numbers on the daily HIV prevention pill. 7

Trevor Mundel Hasina Subedar Linda Gail Bekker Anna Maria Van Niekerk
Mail & Guardian: Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill – The Mail & Guardian